Form 4: Dyne Therapeutics CEO Sells Shares for Tax Obligations

Dyne Therapeutics CEO John Cox sold 2,732 shares of common stock at $14.90 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• John Cox, CEO & President and a Director of Dyne Therapeutics, Inc. (DYN), reported a transaction on March 5, 2026.
• The transaction involved the sale of 2,732 shares of Dyne Therapeutics Common Stock at a price of $14.90 per share.
• This sale was non-discretionary, automatically executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on December 4, 2024.
• The sale was conducted pursuant to a Rule 10b5-1 plan, indicating it was pre-scheduled and not a discretionary trade.
• Following the transaction, Mr. Cox directly beneficially owns 374,145 shares of Common Stock, which includes 279,895 unvested RSUs.
• Additionally, Mr. Cox indirectly beneficially owns 72,000 shares of Common Stock, held in four separate trusts (18,000 shares each) for the benefit of a child.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction for tax purposes and does not reflect a change in management's confidence or the company's operational performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The automatic sale is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1, and the sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that sales of company stock by executives to cover tax obligations upon the vesting of restricted stock units are a common and routine occurrence across all industries, particularly in biotechnology where equity compensation is prevalent.

Related Party Transactions

• Shares are held indirectly in four separate trusts for the benefit of a child of the Reporting Person, totaling 72,000 shares.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes by an executive, not indicative of a change in company fundamentals or management's outlook.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of shares by an executive to cover tax obligations related to RSU vesting. It does not provide new information regarding Dyne Therapeutics' operational performance, strategic direction, or financial health. Therefore, a seasoned investor or institution would likely maintain their current position, as this event does not alter the fundamental investment thesis for the stock.

Keywords

Dyne Therapeutics, DYN, John Cox, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan